54results about How to "High synthetic activity" patented technology

The invention provides methods, kits, and compositions for enhancing synthesis of DNA involving a carboxylate ion-supplying substance that is effective in promoting DNA synthesis in enzymatic DNA synthesis reactions. The invention further provides a thermostable DNA polymerase-related factor derived from Thermococcus species, which has an activity to promote the DNA synthesis activity of DNA polymerase or which binds to DNA polymerase.

The invention provides an iron-based catalyst for preparation of low carbon olefin from synthetic gas. The catalyst contains Fe3O4 as a main active component, and also contains one or two or above assistant M for modification, and M is selected from Si, Al, Mn, K, Cu, Na, Zr, V and Zn. The content of oxide of the assistant in the catalyst is 0-30wt%. The catalyst has the following advantages: 1, particles of the catalyst have regular spherical morphology, uniform space distribution, narrow dimension distribution, and average particle size of 30nm; 2, the catalyst has the characteristics of cheap and easily available raw materials, simple preparation method, low cost, and suitableness for industrial production; 3, the catalyst has good mechanical strength, wear resistance and compression resistance, and is suitable for being applied in fixed beds, fluidized beds and slurry beds; and 4, the catalyst has high Fischer-Tropsch synthesis activity and high low-carbon olefin selectivity, the single-pass conversion rate can reach above 95%, the methane selectivity is lower than 15%, the olefin / paraffin ratio (O / P) is 2-6, and the low-carbon olefin yield can reach 40-100g / m<3>(CO+H2).

The invention discloses a ruthenium system ammonia synthesis catalyst using a graphitization activated carbon as a carrier and a preparation method of the catalyst. The ruthenium system ammonia synthesis catalyst is as shown in Ru-X-K / AC, wherein Ru represents that a precursor is a water-soluble chloride-free ruthenium complex or ruthenium chloride; X represents a metal adjuvant and is one or more of nitrate, acetate, carbonate, metallic oxide and hydroxide of rare-earth metal or alkaline-earth metal; AC represents a graphitization activated carbon carrier, and K represents a kalium adjuvant, namely potassium hydroxide, potassium nitrate, potassium acetate and potassium carbonate; the graphitization activated carbon which has the advantages of high specific surface area, high graphitization and low oxygen content is utilized as the carrier, and the ammonia synthesis catalyst is prepared through steps such as secondary graphitization of graphitization activated carbon, preparation of precursor and preparation of catalyst. The ruthenium system ammonia synthesis catalyst has the advantages that the graphitization activated carbon has large specific surface area and pore volume, enough place is provided for metal segregation, the graphitization degree is high, the oxygen content is low, the methanation resisting capacity of the catalyst is strong, and the stability is good.

A process for preparing a catalyst precursor includes forming a slurry of particles of an insoluble metal compound, where the metal of the insoluble metal compound is an active catalyst component, with particles and / or one or more bodies of a pre-shaped catalyst support in a carrier liquid. The particles of the insoluble metal compound are thus contacted with the particles and / or the one or more bodies of the pre-shaped catalyst support. A treated catalyst support is thereby produced. Carrier liquid is removed from the slurry to obtain a dried treated catalyst support, which either directly constitutes the catalyst precursor, or is optionally calcined to obtain the catalyst precursor.

The invention discloses a rare earth element-doped BaZrO3-delta-based perovskite-type Ru-loading ammonia-synthesis catalyst and a preparation method thereof. The rare earth element-doped BaZrO3-delta-based perovskite-type Ru-loading ammonia-synthesis catalyst utilizes a rare earth element-doped BaZrO3-delta-based perovskite-type composite oxide as a carrier having a molecular formula of Ba1-xLnx+yZr1-yO3-delta and comprises Ru as an active component. A rare earth element doping amount is 1-20wt% of the total amount of the carrier. K2RuO4 is utilized as a precursor of the active component and is directly dipped into the carrier, wherein the Ru loading amount is 0.5-10wt% of the carrier amount. The preparation method has simple processes, adopts simple equipment, does not need an auxiliary agent, and has a low precious metal use amount. The rare earth element-doped BaZrO3-delta-based perovskite-type Ru-loading ammonia-synthesis catalyst has good low-temperature low-pressure activity and high stability.

The invention discloses a bifunctional glutathione synthetase mutant, and a nucleotide sequence, a preparation method and an application thereof. At least one of sites in the third position, the 123rd position, the 161st position, the 194th position, 382nd position and 390th position of the amino acid sequence of a GshF mutant is different from the corresponding sites of the wild GshF amino acid sequence of Streptococcus salivarius in amino acids in order to obtain the GshF mutant having a high synthesis activity, a fast reaction rate and a good conversion efficiency. The synthesis vitality of a GshF-4 mutant is improved 12.8 times, the specific vitality is improved 11 times, the optimum temperature is increased by 20 DEG C, the vitality keeps at 91.3% after standing at 55 DEG C for 60 min, an immobilized enzyme of the GshF-4 mutant allows the concentration of GSH to reach 21 g / L when participating in the catalytic synthesis of the GSH at 50 DEG C under a pH value of 8.0 for 60 min, can be continuously used for 300 times or more, and has very good operating stability.

The present invention relates to a novel catalyst which has a molecular sieving effect (or shape selectivity) and has excellent catalytic activity, and particularly to a catalyst which includes a core made of a zeolite particle having a particle size of not more than 10 μm and a zeolite layer covering the core, wherein as measured by X-ray photoelectron spectroscopy, an outermost surface of the catalyst has a silica / alumina molar ratio of not less than 800, the core made of the zeolite particle has an average silica / alumina molar ratio of not more than 300, and the zeolite layer has an aluminum concentration increasing inward from an outer surface of the catalyst.

Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and / or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.

CrtW carotenoid ketolases are provided that are useful for the production of astaxanthin and other cyclic ketocarotenoids. The mutant ketolase genes of the present invention encode polypeptides characterized by an improvement in astaxanthin synthesis activity when converting cyclic hydroxylated carotenoid intermediates into astaxanthin. Expression of the mutant carotenoid ketolases in heterologous hosts enabled increased production of astaxanthin relative to the Sphingomonas melonis DC18 CrtW.

The present invention relates to a mutant prokaryotic penicillin G acylase derived from a wild-type penicillin G acylase characterized in that the mutant is having an amino acid substitution at one or more amino acid positions selected from the group consisting of amino acid positions A3, A77, A90, A144 A192, B24, B109, B148, B313, B460 and B488 according to the amino acid numbering of the Escherichia coli penicillin G acylase having the amino acid sequence depicted in SEQ ID No: 1.

The present invention provides a method for preparing cell extract for high-performance cell-free protein synthesis reactions, comprising the elimination of low molecular weight substances that have protein synthesis inhibitory activity, from cell extracts that have cell-free protein synthesis activity, by such methods as dialysis, gel filtration and ultrafiltration. Also provided is a ready-made cell-extract for cell-free protein synthesis employing this method. Furthermore, the formation of insoluble matter can be reduced by performing the process for eliminating the low molecular weight substances that inhibit protein synthesis in the co-presence of ATP, GTP or amino acids, so as to stabilize the cell extract.

The present invention enables production of a plant resistant to environmental stresses including drought stress. The invention increases stress resistance to a plant by increasing raffinose content in the plant.

Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and / or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.

The present invention relates to a mutant prokaryotic penicillin G acylase derived from a wild-type penicillin G acylase characterized in that the mutant is having an amino acid substitution at one or more amino acid positions selected from the group consisting of amino acid positions A3, A77, A90, A144 A192, B24, B109, B148, B313, B460 and B488 according to the amino acid numbering of the Escherichia coli penicillin G acylase having the amino acid sequence depicted in SEQ ID No: 1.

The invention discloses recombinant saccharomyces cerevisiae for producing gastrodin by using glucose and application of the recombinant saccharomyces cerevisiae. The construction method of the engineering strain comprises the step of enabling recipient bacteria to express UDP-glucosyltransferase derived from hedyotis diffusa. The recombinant saccharomyces cerevisiae does not express an ARO7 gene, contains genes AsUGTsyn, CARsyn, PPTcg-1syn and ubiCsyn capable of expressing the gastrodin synthesis pathway and genes ppsA, tktA, ARO1, ARO2 and ARO4 mutant ARO4K229L genes capable of expressing gastrodin precursor synthesis enhancement. According to the application, a metabolic pathway for synthesizing gastrodin from glucose is constructed in food-grade saccharomyces cerevisiae by introducing new glycosyl transferase, the fermentation yield of gastrodin in a 250mL shake flask reaches 2.1 g / L through a genome integration technology and improvement of a precursor anabolic flow, a foundation is laid for large-scale industrial production, and important economic values and social benefits are achieved.

The invention discloses a pharmaceutical composition for promoting fracture repair. The pharmaceutical composition is prepared by matching the following bulk pharmaceutical chemicals: picris japonica, nettle, almond, eritrichium, cucurbitacin E and justicidin A, can be used for preparing various medical forms according to the conventional preparation technology, and is effective in treatment for promoting fracture repair.

The present invention provides a method for producing a polyisoprenoid with which it is possible to enhance the rubber synthesis activity of rubber particles to increase natural rubber production. The present invention relates to a method for producing a polyisoprenoid in vitro, which involves the use of a gene coding for a cis-prenyltransferase (CPT) family protein and a gene coding for a Nogo-B receptor (NgBR) family protein, and further involves the use of rubber particles bound to proteins encoded by these genes; or a method for producing a polyisoprenoid, which includes introducing into a plant a vector in which a promoter having a promoter activity that drives laticifer-specific gene expression is linked to a gene coding for a CPT family protein and a gene coding for a NgBR family protein, to express proteins encoded by the genes specifically in laticifers.

The invention relates to a modified biphenyl type dianhydride intermediate containing a cyano side chain, and the structural formula is as follows, in the structural formula, R is -O-R1 or -S-R1 or -CN. The intermediate can be prepared by two preparation methods, and the first preparation method comprises the following steps: (1) the preparation of a second compound; (2) the preparation of a third compound; (3) the preparation of a fourth compound; (4) the preparation of a fifth compound; and (5) the preparation of the modified biphenyl type dianhydride intermediate containing the cyano side chain. The second preparation method comprises the following steps: (1) the preparation of the second compound; (2) the preparation of the third compound; (3) the preparation of the fourth compound-a; (4) the preparation of the fourth compound-b; (5) the preparation of the fifth compound; and (6) the preparation of the modified biphenyl type dianhydride intermediate containing the cyano side chain.

The present invention relates to a novel catalyst which has a molecular sieving effect (or shape selectivity) and has excellent catalytic activity, and particularly to a catalyst which includes a core made of a zeolite particle having a particle size of not more than 10 μm and a zeolite layer covering the core, wherein as measured by X-ray photoelectron spectroscopy, an outermost surface of the catalyst has a silica / alumina molar ratio of not less than 800, the core made of the zeolite particle has an average silica / alumina molar ratio of not more than 300, and the zeolite layer has an aluminum concentration increasing inward from an outer surface of the catalyst.

The present invention provides a stable and viable biocatalyst with high activity and operational stability and method of immobilization thereof. The immobilization process is based on the principle of entrapment of partially purified enzyme precipitate which is simultaneously aggregated by cross linking agent like glutaraldehyde and further entrapped in a combination of natural polymer like gelatin and synthetic polymer like polyvinyl alcohol with effective gelation under mild conditions of temperature and pH, resulting in a stable biocatalyst. The enzymes immobilized by the above process include Penicillin acylase from rE. coli RE III (pKA18), Novel Penicillin acylase from Achromobacter sp (CCM4834) expressed in rE. coli BL21 (pK1P1) CCM 7394 and rE. coli RE III (pKX1P1).

The invention discloses a pharmaceutical composition for promoting traumatic fracture coalescence. The pharmaceutical composition is prepared by matching the following bulk pharmaceutical chemicals: vulture feces, scammonic sub-butter, heteropappus altaicus, scinncus officinalis linnaeus, hemiphroside B and justicidin A, can be used for preparing various medical forms according to the conventional preparation technology, and is beneficial to promoting traumatic fracture coalescence.

The present invention relates to mutants of penicillin G acylase from Achromobacter sp. CCM 4824 and uses thereof, and more specifically relates to Mutants of penicillin G acylase in a wild type penicillin G acylase protein sequence including an Alpha subunit shown in SEQ ID NO.1 and a Beta subunit shown in SEQ ID NO.2 and a method of preparing (synthesizing) Beta-Lactam antibiotics by using theMutants of penicillin G acylase, wherein the Mutants of penicillin G acylase select at least one mutation from a population consisting of A65AlphaV, A102AlphaE, A106AlphaT, D74BetaQ, R120BetaC, T176BetaS, Y180BetaS, T193BetaI, Y248BetaF, F254BetaY, T292BetaS, F343BetaY, E366BetaV and T485BetaS as the feature. The Mutants of penicillin G acylase from Achromobacter sp. CCM 4824, having a specific mutation form, are characterized by multiple syntheses with high efficiency for multiple semi-synthesized Beta-Lactam antibiotics.

The invention discloses a pharmaceutical composition for promoting fracture coalescence. The pharmaceutical composition is prepared by matching the following bulk pharmaceutical chemicals: vulture feces, nettle, lemmaphyllum microphyllum, eritrichium, hemiphroside B and justicidin A, can be used for preparing various medical forms according to the conventional preparation technology, and is effective in treatment for promoting fracture coalescence.

The invention discloses pyrimidine EGFRT790M inhibitors and their medicinal salt. The pyrimidine EGFRT790M inhibitors have a general structural formula shown in the following description. By a classical drug design and a structure-function relationship research method, an oxygen atom on a substituent group at a 4-site of a WZ4002 pyrimidine ring is replaced by an imino group, a methoxy group at the 2-site of a phenyl ring is further removed, the substituent group at a 4-site of the phenyl ring is subjected to structural modification, the modified structure replaces the original Michael receptor, seven unknown novel pyrimidine compounds are designed and synthesized so that more structure types of the pyrimidine EGFRT790M inhibitors are obtained. An in-vitro tumor activity test result shows that the compounds 8a and 8f have strong EGFRT790M kinase propagation inhibition activity. The pyrimidine EGFRT790M inhibitors provide reference for further design and synthesis of novel EGFRT790M inhibitors with higher activity and better selectivity.

The invention discloses a croton acylated catapol derivative which is prepared by esterifying catalpol and crotonic anhydride. The invention provides a corresponding preparation method and application, and the preparation method comprises the following steps: 1) dissolving catalpol into triethylamine, adding a catalyst 4-dimethylaminopyridine, adding crotonic anhydride under protection of nitrogengas, reacting for 12-36 hours at a temperature of 30-90 DEG C, and drying triethylamine by distilling to obtain a product, wherein a molar ratio of crotonic anhydride to catalpol is (6-18) to 1, anda molar ratio of 4-dimethylaminopyridine to catalpol is 1 to (9.5-10.5); and 2) dissolving the product in the step 1) into dichloromethane, adding an alkaline agent, standing and layering, discardingan upper-layer water phase, drying an organic phase to remove water, drying dichloromethane by distilling, purifying and separating, evaporating-drying, and filtering to obtain the catapol derivative.The catapol derivative has good anti-ageing activity, improves blood-brain barrier permeability of catapol, and has an esterification rate of 99.16%.

The present invention relates to mutants of penicillin G acylase from Achromobacter sp. CCM 4824 and uses thereof, and more specifically relates to Mutants of penicillin G acylase in a wild type penicillin G acylase protein sequence including an Alpha subunit shown in SEQ ID NO.1 and a Beta subunit shown in SEQ ID NO.2 and a method of preparing (synthesizing) Beta-Lactam antibiotics by using the Mutants of penicillin G acylase, wherein the Mutants of penicillin G acylase select at least one mutation from a population consisting of A65AlphaV, A102AlphaE, A106AlphaT, D74BetaQ, R120BetaC, T176BetaS, Y180BetaS, T193BetaI, Y248BetaF, F254BetaY, T292BetaS, F343BetaY, E366BetaV and T485BetaS as the feature. The Mutants of penicillin G acylase from Achromobacter sp. CCM 4824, having a specific mutation form, are characterized by multiple syntheses with high efficiency for multiple semi-synthesized Beta-Lactam antibiotics.

CrtW carotenoid ketolases are provided useful for the production of astaxanthin. The ketolases genes of the present invention exhibit improved ketolase activity when converting cyclic hydroxylated carotenoid intermediates into astaxanthin. Recombinant expression of the present carotenoid ketolases in host cell producing cyclic hydroxylated carotenoid intermediates enabled increased production of astaxanthin.

A process for preparing a catalyst precursor includes forming a slurry of particles of an insoluble metal compound, where the metal of the insoluble metal compound is an active catalyst component, with particles and / or one or more bodies of a pre-shaped catalyst support in a carrier liquid. The particles of the insoluble metal compound are thus contacted with the particles and / or the one or more bodies of the pre-shaped catalyst support. A treated catalyst support is thereby produced. Carrier liquid is removed from the slurry to obtain a dried treated catalyst support, which either directly constitutes the catalyst precursor, or is optionally calcined to obtain the catalyst precursor.

The invention discloses 3-(indol-5-yl)-indazole derivatives. The structure of the 3-(indol-5-yl)-indazole derivatives is shown in formula (I) or (II), in formula (I), R1 is selected from substituted or unsubstituted aryl group or alkyl group; R2 is selected from hydrogen or benzyl group; and R3 is selected from hydrogen or alcoholic group. In formula (II), R1 is selected from nitro group or aminogroup. The research result shows that most of 3-(indol-5-yl)-indazole derivatives have better anti-inflammatory activity and can improve the druggability defect of the lead compound.

Provided is a method for producing rubber particles with a reduced coagulation tendency. The present invention relates to a method for producing rubber particles with a reduced coagulation tendency, the method including a step of performing protein synthesis in the presence of both rubber particles and a cell-free protein synthesis solution containing an mRNA coding for a rubber elongation factor (REF) family protein to bind the REF family protein to the rubber particles.